Chemistry Reference
In-Depth Information
activity landscapes:Application to drug discovery. Angew Chem Int Ed Engl. 2011, 50:
11633-11636.
[60] Schneider G, Hartenfeller M, Reutlinger M, Tanrikulu Y, Proschak E, Schneider P.
Voyages to the unknown: adaptive design of bioactive compounds.Trends Biotechnol.
2009, 27:18-26
[61] Miranker A, Karplus M. Functionality maps of binding sites: a multiple copy simultaneous
search method. Proteins. 1991, 11: 29-34
[62] Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to
macromolecule-ligand interactions. J Mol Biol. 1982, 161:269-288
[63] Cramer RD, Patterson DE, Bunce JD. Comparative molecular field analysis (CoMFA). 1.
Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc.1988, 110:5959-
5967
[64] Jackson RC. Update on computer-aided drug design. Curr Opin Biotechnol. 1995, 6:646-
651
[65] Bo-Lm HJ (1996) Current computational tools for
de novo
ligand design. Curr Opin
Biotechnol. 1996, 7:433-436
[66] Bohacek RS, McMartin C. Modern computational chemistry and drug discovery: structure
generating programs. Curr Opin Chem Biol. 1997, 1:157-161
[67] Marrone TJ, Briggs JM, McCammon JA. Structure-based drug design: computational
advances. Annu Rev Pharmacol Toxicol. 1997, 37:71-90
[68] Kubinyi H. Combinatorial and computational approaches in structure-based drug design.
Curr Opin Drug Discov Devel. 1998, 1:16-27
[69] Moon JB, Howe WJ. Computer design of bioactive molecules: a method for receptor-based
de novo
ligand design. Proteins. 1991, 11:314-328
[70] Bohacek RS, McMartin C. Multiple highly diverse structures complementary to enzyme
binding sites: results of extensive application of a
de novo
design method incorporating
combinatorial growth. J Am Chem Soc. 1994, 116:5560-5571
[71] Schneider G, Neidhart W, Giller T, Schmid G. 'Scaffold hopping' by topological
pharmacophore search: a contribution to virtual screening. Angew Chem Int Ed Engl. 1999,
38:2894-2896
[72]
Alig L, Alsenz J, Andjelkovic M, Bendels S, Benardeau A, Bleicher K, Bourson A, David-
Pierson P, Guba W, Hildbrand S, Kube D, Lubbers T, Mayweg AV, Narquizian R,
Neidhart W, Nettekoven M, Plancher JM, Rocha C, Rogers-Evans M, RO ver S, Schneider
G, Taylor S, Waldmeier P. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists
for the treatment of obesity. J Med Chem. 2008, 51:2115-2127
[73]
Mauser HG. Recent developments in
de novo
design and scaffold hopping. Curr Opin Drug
Discov Devel. 2010, 11:365-374
[74]
Langdon SR, Ertl P, Brown N. Bioisosteric replacement and scaffold hopping in lead
generation and optimization. Mol Inf. 2010, 29:366-385
[75]
Bailey D, Brown D. High-throughput chemistry and structure-based design: survival of the
smartest. Drug Discov Today. 2001, 6:57-59
[76]
Bleicher KH, Bo HM, MuIler K, Alanine AI. Hit and lead generation: beyond high-
throughput screening. Nat Rev Drug Discov, 2003, 2:369-378
[77]
Schneider G. Virtual screening: an endless staircase? Nat Rev Drug Discov. 2010, 9:273-
276
